Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in two upcoming investment conferences.
Angion will participate in two investment conferences in March. At the Cowen 42nd Annual Healthcare Conference, Angion’s President and CEO Dr. Jay Venkatesan will participate in a kidney disease/fibrosis panel. At the Oppenheimer 32nd Annual Healthcare Conference, Dr. Venkatesan will participate in a Fireside Chat with Oppenheimer Senior Biotech Analyst Justin Kim. Details are as follows:
Cowen 42nd Annual Healthcare Conference (Virtual)
Oppenheimer 32nd Annual Healthcare Conference (Virtual)
Webcasts of both events will be accessible online by visiting the events and presentations page under the investors section of Angion’s website at https://ir.angion.com/events-presentations. The webcasts will remain archived on Angion’s website for approximately 30 days.
About Angion Biomedica Corp.
Angion is committed to transforming the treatment paradigm for patients suffering from fibrotic diseases for which there are no approved medicines or where existing approved medicines have known limitations. Angion’s lead product candidate is ANG-3070, a highly-selective oral tyrosine kinase receptor inhibitor in development for the treatment of fibrotic kidney and lung diseases. Enrollment is ongoing in a dose-finding Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases (NCT04939116). Additionally, Angion has preclinical programs focused on a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor. For more information, please visit www.angion.com.
Contact
David Miller
Director of Communications & Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.70 |
| Daily Change: | -0.38 -7.48 |
| Daily Volume: | 24,605 |
| Market Cap: | US$50.710M |
December 12, 2024 November 13, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
